Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents

  • Tom Meade
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 210)


In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention). ASA is therefore recommended for these people. However, in primary prevention—reducing risk in those so far free of clinically manifest episodes—pthe benefit is of the same order as the bleeding hazard, (which is much the same in both primary and secondary prevention contexts). The use of other effective agents such as statins further emphasises the even balance between benefit and hazard in primary prevention. Six primary prevention trials are reviewed, first singly and then in a meta-analysis based on individual patient data. ASA reduced non-fatal myocardial infarction by about 25%. However, death from coronary heart disease (CHD) was not significantly reduced (by 5%), nor was any vascular death (3%). There was a non- significant reduction in strokes of 5%, this being the net result of an 8% reduction in non-fatal stroke and a 21% increase in stroke death (mainly from haemorrhagic events), both effects being non-significant. Serious vascular events (MI, stroke or vascular death) were significantly reduced by 12%, mainly due to the large effect on non-fatal MI. About 1650 people would need to be treated with ASA for a year to avoid one serious vascular event, which contrasts with the 10-20 events avoided in secondary prevention by treating 1,000 patients for a year. Other primary prevention trials not included in the meta-analysis have also reported no benefits in MI or stroke, but the findings of still unpublished trials are awaited. Recently, however, encouraging results have come from meta-analyses of the effects of ASA on cancer incidence and mortality and on its effects on cancer metastasis, particularly for adenocarcinomas. Typically, reductions in these measures have been around 30% following treatment for four or five years, but more in several instances. These results alter the balance in primary prevention between benefit and hazard as it appears for arterial events alone, tipping it towards the use of ASA. Consequently, new guidelines on advice and decisions on ASA in primary prevention are now needed. Low dose ASA, eg. 75 mg daily is as effective as higher doses for all the vascular and cancer benefits established in the meta-analyses, and it causes less serious bleeding than higher doses.


Ankle brachial index Aspirin Cancer Clopidogrel Coronary heart disease (CHD) Diabetes Myocardial infarction (MI) Primary prevention Stroke Transient ischaemic attack (TIA) 



I am grateful to Professor Colin Baigent for his advice on the meta-analysis, to Liz Turner for her help with further information on Table 7 and Professor Gerry Fowkes and Dr. Izzy Butcher for further information on Table 15. Professor Bianca De Stavola gave statistical assistance. Professor Peter Rothwell kindly commented on the sections dealing with cancer. I am particularly grateful to Donna Davoren for her help with the manuscript.


  1. A Study of Cardiovascular Events in Diabetes (ASCEND) Study (2008) Accessed 23 April 2009
  2. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRefGoogle Scholar
  3. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Study (2008) Accessed 23 April 2009
  4. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860PubMedCrossRefGoogle Scholar
  5. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840PubMedCrossRefGoogle Scholar
  6. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706–1717PubMedCrossRefGoogle Scholar
  7. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087PubMedCrossRefGoogle Scholar
  8. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRefGoogle Scholar
  9. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1607–1621PubMedCrossRefGoogle Scholar
  10. Collaborative Group of the Primary Prevention Project (PPP) (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357(9250):89–95CrossRefGoogle Scholar
  11. De BG, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G et al (2007) Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8:21CrossRefGoogle Scholar
  12. Elwood PC, Williams WO (1979) A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J Royl Coll GPs 29:413–416Google Scholar
  13. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1(905):436–440PubMedCrossRefGoogle Scholar
  14. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373(9671):1301–1309PubMedCrossRefGoogle Scholar
  15. ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 268(10):1292–1300CrossRefGoogle Scholar
  16. Farrell B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54(12):1044–1054PubMedCrossRefGoogle Scholar
  17. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(9573):1603–1613PubMedCrossRefGoogle Scholar
  18. Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ (1991) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20:384–392PubMedCrossRefGoogle Scholar
  19. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841–848PubMedCrossRefGoogle Scholar
  20. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351(9118):1755–1762PubMedCrossRefGoogle Scholar
  21. Meade TW, Brennan PJ (2000) Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321:13–17PubMedCrossRefGoogle Scholar
  22. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S et al (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533–537PubMedCrossRefGoogle Scholar
  23. Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233–241CrossRefGoogle Scholar
  24. Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H et al (2003) Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 20(12):897–903PubMedCrossRefGoogle Scholar
  25. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300(18):2134–2141PubMedCrossRefGoogle Scholar
  26. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K et al (1988) Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296:313–316PubMedCrossRefGoogle Scholar
  27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293–1304PubMedCrossRefGoogle Scholar
  28. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741–1750PubMedCrossRefGoogle Scholar
  29. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41PubMedCrossRefGoogle Scholar
  30. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591–1601Google Scholar
  31. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189PubMedCrossRefGoogle Scholar
  32. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19):2411–2420PubMedCrossRefGoogle Scholar
  33. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Investigators (2001) Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes Without ST-Segment Elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Investigators. N Engl J Med 345:494–502CrossRefGoogle Scholar
  34. The SALT Collaborative Group (1991) Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345–1349CrossRefGoogle Scholar
  35. The Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians’ health study. N Eng J Med 321:129–135CrossRefGoogle Scholar
  36. U.S. Preventive Services Task Force (2009) Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150:396–405, Ref type: GenericGoogle Scholar
  37. Weiss HJ, Aledort LM (1967) Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet 2:495–497PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Non-Communicable Disease EpidemiologyLondon School of Hygiene & Tropical MedicineLondonUK

Personalised recommendations